206 related articles for article (PubMed ID: 25608975)
1. Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.
Araínga M; Guo D; Wiederin J; Ciborowski P; McMillan J; Gendelman HE
Retrovirology; 2015 Jan; 12():5. PubMed ID: 25608975
[TBL] [Abstract][Full Text] [Related]
2. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
3. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
4. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Nowacek AS; McMillan J; Miller R; Anderson A; Rabinow B; Gendelman HE
J Neuroimmune Pharmacol; 2010 Dec; 5(4):592-601. PubMed ID: 20237859
[TBL] [Abstract][Full Text] [Related]
5. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
6. Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
Martinez-Skinner AL; Araínga MA; Puligujja P; Palandri DL; Baldridge HM; Edagwa BJ; McMillan JM; Mosley RL; Gendelman HE
PLoS One; 2015; 10(12):e0145966. PubMed ID: 26716700
[TBL] [Abstract][Full Text] [Related]
7. The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Zhang G; Guo D; Dash PK; Araínga M; Wiederin JL; Haverland NA; Knibbe-Hollinger J; Martinez-Skinner A; Ciborowski P; Goodfellow VS; Wysocki TA; Wysocki BJ; Poluektova LY; Liu XM; McMillan JM; Gorantla S; Gelbard HA; Gendelman HE
Nanomedicine; 2016 Jan; 12(1):109-22. PubMed ID: 26472049
[TBL] [Abstract][Full Text] [Related]
8. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Nowacek AS; Balkundi S; McMillan J; Roy U; Martinez-Skinner A; Mosley RL; Kanmogne G; Kabanov AV; Bronich T; Gendelman HE
J Control Release; 2011 Mar; 150(2):204-11. PubMed ID: 21108978
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Gautam N; Roy U; Balkundi S; Puligujja P; Guo D; Smith N; Liu XM; Lamberty B; Morsey B; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2013 Jul; 57(7):3110-20. PubMed ID: 23612193
[TBL] [Abstract][Full Text] [Related]
10. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
Martinez-Skinner AL; Veerubhotla RS; Liu H; Xiong H; Yu F; McMillan JM; Gendelman HE
J Proteome Res; 2013 May; 12(5):2282-94. PubMed ID: 23544708
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
12. Modulating cellular autophagy for controlled antiretroviral drug release.
Thomas MB; Gnanadhas DP; Dash PK; Machhi J; Lin Z; McMillan J; Edagwa B; Gelbard H; Gendelman HE; Gorantla S
Nanomedicine (Lond); 2018 Sep; 13(17):2139-2154. PubMed ID: 30129397
[TBL] [Abstract][Full Text] [Related]
13. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Puligujja P; Araínga M; Dash P; Palandri D; Mosley RL; Gorantla S; Poluektova L; McMillan J; Gendelman HE
Antiviral Res; 2015 Aug; 120():85-8. PubMed ID: 26026666
[TBL] [Abstract][Full Text] [Related]
15. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
16. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.
Gautam N; Puligujja P; Balkundi S; Thakare R; Liu XM; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2014 Dec; 58(12):7510-9. PubMed ID: 25288084
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
19. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
20. Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral Therapy.
Gill AJ; Kovacsics CE; Vance PJ; Collman RG; Kolson DL
J Virol; 2015 Oct; 89(20):10656-67. PubMed ID: 26269184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
